Amsonic acid
Amsonic acid is an orally active weak estrogen receptor ligand with uterotrophic activity. In the weanling female rat model, Amsonic acid exhibits a uterotrophic effect consistent with that of diethylstilbestrol at equiactive doses. Amsonic acid can also be used in studies related to erectile dysfunction.
For research use only. We do not sell to patients.
- CAS No.: 28096-93-7
- Formula: C14H14N2O6S2
- Molecular Weight:370.40
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
Amsonic acid exhibits weak binding to estrogen receptors isolated from rabbit uteri, alongside other tested chemicals including 4-nitrotoluene, DNSDSA, and MNBSA[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:CD Sprague-Dawley Rat (female, weanling)[1]
-
Dosage:0.1 mg/kg; 1 mg/kg; 10 mg/kg; 30 mg/kg; 100 mg/kg; 300 mg/kg; 1000 mg/kg; 3000 mg/kg (i.p.); 1000 mg/kg; 3000 mg/kg (p.o.)
-
Administration:i.p.; single dose; p.o.; single dose
-
Result:Caused no change in relative uterine weight at 0.1 and 1 mg/kg i.p..
Produced equivocal effects at 10, 30, and 100 mg/kg i.p., with only the 30 mg/kg dose showing a statistically significant 16% increase in relative uterine weight.
Induced a statistically significant 66% increase in relative uterine weight at 300 mg/kg i.p..
Caused a statistically significant 50% increase in relative uterine weight at 1000 mg/kg i.p., with no overt toxicity observed.
Resulted in toxicity at 3000 mg/kg i.p., with 2 out of 6 animals dying within 24 hours.
Produced distinct uterotropic responses with no toxicity at 1000 and 3000 mg/kg p.o..
Caused a statistically significant increase in relative uterine weight for a workplace sample at 300 mg/kg i.p., consistent with the commercial sample.
Showed a time course of uterine weight gain after 300 mg/kg i.p. similar to that of equiactive 0.01 mg/kg i.p. diethylstilbestrol, with a multiphasic response including an early and late phase.
Chemical Information
-
CAS No. 28096-93-7
-
Molecular Weight 370.40
-
Formula C14H14N2O6S2
-
SMILES
O=S(O)(C1=C(C=CC(N)=C1)/C=C/C2=C(C=C(C=C2)N)S(=O)(O)=O)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
-
How to Select a Suitable Non-Mouse Animal Model
Selecting a suitable non-mouse animal model is a structured decision based on the research question, required anatomy or physiology, disease mechanism, endpoint feasibility, translational relevance, and ethical justification. Non-mouse models are preferred when mice cannot reproduce key human-relevant features, such as organ size, surgical anatomy, cardiovascular physiology, neuroanatomy, immune features, pharmacology, toxicology, or long-term clinical procedures. Candidate species may include rats, rabbits, guinea pigs, ferrets, zebrafish, pigs, sheep, goats, dogs, cats, horses, and non-human primates, but each species must be justified by its specific scientific advantage rather than convenience or tradition. Unresolved questions include how to quantify translational superiority across species, how to balance increased biological relevance against higher ethical burden, and when human-derived systems or new approach methodologies should replace animal use.
-
How to Choose the Right Model Animal
Choosing the right model animal is a validity-driven decision in which the species, strain, sex, age, genetic background, disease-induction method, outcome measures, and welfare burden must match the scientific question rather than laboratory tradition or convenience. A model should be selected by judging face validity, construct validity, and predictive validity: whether it resembles the human phenotype, whether it reproduces relevant mechanisms, and whether results are likely to predict human biology or treatment response. Animal studies often fail to translate because of species differences, weak disease resemblance, poor experimental design, inadequate reporting, publication bias, and underuse of randomization, blinding, and sample-size justification. Unresolved questions include how to rank competing models objectively, how much human-disease complexity must be reproduced for a given objective, and when non-animal systems such as organoids, ex vivo tissue, or computational models
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)